Abstract

The proposal has significance in that it would establish the scientific capability, the administrative expertise and essential physical equipment for: 1. On-going pharmacologic study of established, effective oncologic drugs used in treating malignancies of childhood permitting: a. Rational rather than empirical dosage schedules, b. better understanding of toxicity and its prevention, c. comparison of pharmacokinetics in children with published data for adults with a view to determining age related differences, and d. monitoring for compliance to permit better evaluation of individuals, as well as groups of patients, to give the physician an opportunity to secure better compliance should it be lacking. 2. Pharmacologic evaluation of new formulations of drugs used in treating cancer in children. The actual research projected centers around the expertise of Dr. Nelson in applying methodology of cancer drugs to research and cancer problems.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-14
Application #
3101600
Study Section
(SRC)
Project Start
1978-07-01
Project End
1992-06-30
Budget Start
1988-07-08
Budget End
1989-06-30
Support Year
14
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103
Sun, Lin-Lin; Yang, Ri-Yao; Li, Chia-Wei et al. (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307-1316
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Veletic, Ivo; Manshouri, Taghi; Newberry, Kate J et al. (2018) Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol :
El Fakih, Riad; Jabbour, Elias; Ravandi, Farhad et al. (2018) Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 93:286-295
Sankhala, Kamalesh; Takimoto, Chris H; Mita, Alain C et al. (2018) Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs :
Shen, Weining; Ning, Jing; Yuan, Ying et al. (2018) Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74:239-248
Wu, Shaofang; Wang, Shuzhen; Gao, Feng et al. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol 20:78-91
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152

Showing the most recent 10 out of 12418 publications